0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy
Primary Purpose
Peripheral Diabetic Neuropathy
Status
Completed
Phase
Phase 3
Locations
Thailand
Study Type
Interventional
Intervention
0.075% Capsaicin Lotion
placebo
Sponsored by
About this trial
This is an interventional treatment trial for Peripheral Diabetic Neuropathy focused on measuring capsaicin, neuropathic pain, diabetic neuropathy, topical lotion
Eligibility Criteria
Inclusion Criteria:
- DM type 2 over 1 year
- Clinical presentation of peripheral sensory such as burning pain
- DN4 score from 4 points
- Good consciousness to tell their score with informed consent agreement
- No adding dosage of previous pain control medications at least 4 weeks
- HbA1C 6.5-9.0%
Exclusion Criteria:
- Improper application site of skin for topical drugs such as abrasion wound.
- Allergic history of Capsaicin
- No intention to join the study with any reasons
- Other previous medications used that effect to peripheral neuropathy such as Carboplatin, Cisplatin, Colchicine, Dapsone, Etoposide, Ethambutol, Indomethacin, Isoniazid, Lithium, Metronidazole, Phenytoin, Pyridoxine, Statins, Stavudine (d4T) or conditions worsening peripheral nerves following that poor nutrition, kidney failure, chronic alcoholism, vitamin deficiency, Hypothyroidism
Sites / Locations
- Thammasat University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
0.075% Capsaicin Lotion
Placebo Lotion
Arm Description
0.075% Capsaicin Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
Placebo Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
Outcomes
Primary Outcome Measures
Visual analog scale (0-100 mm.)
scale
Secondary Outcome Measures
Short-form McGill Pain Questionnaire(SF-MPQ)
scale
Neuropathic Pain Scale (NPS)
scale
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03113448
Brief Title
0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy
Official Title
0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy: A Randomized, Double- Blind, Crossover, Placebo-Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
January 19, 2017 (Actual)
Primary Completion Date
April 21, 2017 (Actual)
Study Completion Date
January 31, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Thammasat University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To study that 0.075% capsaicin lotion is safe, well tolerated and provide significant pain relief in patients with PDN compared with placebo lotion as a randomized, double- Blind, crossover, placebo-controlled trial
Detailed Description
Neuropathy is one of the most common complications in both type 1 and type 2 diabetes mellitus. The most common symptom is a symmetrical, chronic, axonal, length-dependent sensorimotor polyneuropathy.
Topical capsaicin formulations are widely used to manage pain. Low-concentration creams, lotions, and patches intended for daily skin application have been available in most countries since the early 1980s.
We study 0.075% capsaicin lotion is safe, well tolerated and provide significant pain relief in patients with PDN compared with placebo lotion as a randomized, double- Blind, crossover, placebo-controlled trial for 20 weeks throughout the study in 42 participants. All participants are provided both 0.075% capsaicin lotion and placebo lotion. Each agent will be applied for 8 weeks then stop for 4 weeks, after that another agent will be used for 8 weeks. We keep following up all of them by calling and appointment to get information in effectiveness and adverse effect at 0,2,4,8,12,14,16,20 week, respectively.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Diabetic Neuropathy
Keywords
capsaicin, neuropathic pain, diabetic neuropathy, topical lotion
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Model Description
Randomized controlled trial, double blind
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
42 (Actual)
8. Arms, Groups, and Interventions
Arm Title
0.075% Capsaicin Lotion
Arm Type
Active Comparator
Arm Description
0.075% Capsaicin Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
Arm Title
Placebo Lotion
Arm Type
Placebo Comparator
Arm Description
Placebo Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
Intervention Type
Drug
Intervention Name(s)
0.075% Capsaicin Lotion
Intervention Description
To apply 3-4 times per day, every day until 8 weeks then stop
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
To apply 3-4 times per day, every day until 8 weeks then stop
Primary Outcome Measure Information:
Title
Visual analog scale (0-100 mm.)
Description
scale
Time Frame
20 week
Secondary Outcome Measure Information:
Title
Short-form McGill Pain Questionnaire(SF-MPQ)
Description
scale
Time Frame
20 week
Title
Neuropathic Pain Scale (NPS)
Description
scale
Time Frame
20 week
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
DM type 2 over 1 year
Clinical presentation of peripheral sensory such as burning pain
DN4 score from 4 points
Good consciousness to tell their score with informed consent agreement
No adding dosage of previous pain control medications at least 4 weeks
HbA1C 6.5-9.0%
Exclusion Criteria:
Improper application site of skin for topical drugs such as abrasion wound.
Allergic history of Capsaicin
No intention to join the study with any reasons
Other previous medications used that effect to peripheral neuropathy such as Carboplatin, Cisplatin, Colchicine, Dapsone, Etoposide, Ethambutol, Indomethacin, Isoniazid, Lithium, Metronidazole, Phenytoin, Pyridoxine, Statins, Stavudine (d4T) or conditions worsening peripheral nerves following that poor nutrition, kidney failure, chronic alcoholism, vitamin deficiency, Hypothyroidism
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kongkiat Kulkantrakorn, Professor
Organizational Affiliation
Thammasat University Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Pasiri Sithinamsuwan
Organizational Affiliation
Phramongkutklao College of Medicine
Official's Role
Study Director
Facility Information:
Facility Name
Thammasat University Hospital
City
Pathumthani
ZIP/Postal Code
12120
Country
Thailand
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy
We'll reach out to this number within 24 hrs